GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares have been hammered since the company said it would post no sales or profit growth in the year ahead after all, but what is much more important for the long term is the reshaping taking place — and the new drugs coming down the line…
https://youtu.be/xaFY5fxXfwg